Claudio Passino

List of Publications by Year
in descending order

338 papers	11,581 citations	25034 57 h-index	48315 88 g-index
360 all docs	360 docs citations	360 times ranked	11522 citing authors

#	Article	IF	Citations
1	Biomarkers for the diagnosis and management of heart failure. Heart Failure Reviews, 2022, 27, 625-643.	3.9	135
2	Epidemiological and clinical boundaries of heart failure with preserved ejection fraction. European Journal of Preventive Cardiology, 2022, 29, 1233-1243.	1.8	16
3	The triglyceride/HDL cholesterol ratio and TyG index predict coronary atherosclerosis and outcome in the general population. European Journal of Preventive Cardiology, 2022, 29, e203-e204.	1.8	4
4	Creatine deficiency and heart failure. Heart Failure Reviews, 2022, 27, 1605-1616.	3.9	13
5	High-sensitivity troponins for outcome prediction in the general population: a systematic review and meta-analysis. European Journal of Internal Medicine, 2022, 98, 61-68.	2.2	15
6	Functional connectome of brainstem nuclei involved in autonomic, limbic, pain and sensory processing in living humans from 7 Tesla resting state fMRI. NeuroImage, 2022, 250, 118925.	4.2	21
7	Functional connectome of arousal and motor brainstem nuclei in living humans by 7 Tesla resting-state fMRI. NeuroImage, 2022, 249, 118865.	4.2	20
8	Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis. European Heart Journal Cardiovascular Imaging, 2022, 24, 130-141.	1.2	18
9	Cardiac protection by pirfenidone after myocardial infarction: a bioinformatic analysis. Scientific Reports, 2022, 12, 4691.	3.3	4
10	In Vivo Murine Models of Cardiotoxicity Due to Anticancer Drugs: Challenges and Opportunities for Clinical Translation. Journal of Cardiovascular Translational Research, 2022, , 1.	2.4	2
11	Central Apneas Are More Detrimental in Female Than in Male Patients With Heart Failure. Journal of the American Heart Association, 2022, 11, e024103.	3.7	7
12	RNA-targeting and gene editing therapies for transthyretin amyloidosis. Nature Reviews Cardiology, 2022, 19, 655-667.	13.7	64
13	Critical Comparison of Documents FromÂScientific Societies on CardiacÂAmyloidosis. Journal of the American College of Cardiology, 2022, 79, 1288-1303.	2.8	35
14	Decongestion, kidney injury and prognosis in patients with acute heart failure. International Journal of Cardiology, 2022, 354, 29-37.	1.7	6
15	Response to the Letter: Sleep-Disordered Breathing in Precapillary Pulmonary Hypertension: Is the Prevalence So High? Reference Article: Sleep-Disordered Breathing and Nocturnal Hypoxemia in Precapillary Pulmonary Hypertension: Prevalence, Pathophysiological Determinants and Clinical Consequences by Zheng Z et al., Respiration, 2022, 101, 433-435.	2.6	1
16	Big gamma-glutamyltransferase is associated with epicardial fat volume and cardiovascular outcome in the general population. European Journal of Preventive Cardiology, 2022, 29, 1510-1518.	1.8	2
17	Speckle tracking echocardiography in heart failure development and progression in patients with apneas. Heart Failure Reviews, 2022, 27, 1869-1881.	3.9	7
18	Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin. Heart Failure Reviews, 2022, , .	3.9	5

#	Article	IF	Citations
19	Chemoreflex and Baroreflex Sensitivity Hold a Strong Prognostic Value in Chronic HeartÂFailure. JACC: Heart Failure, 2022, 10, 662-676.	4.1	17
20	Circulating levels and prognostic cutâ€offs of sST2, hsâ€cTnT, and NTâ€proBNP in women vs. men with chronic heart failure. ESC Heart Failure, 2022, 9, 2084-2095.	3.1	15
21	Old and new equations for maximal heart rate prediction in patients with heart failure and reduced ejection fraction on beta-blockers treatment: results from the MECKI score data set. European Journal of Preventive Cardiology, 2022, 29, 1680-1688.	1.8	11
22	Healthy aging: the INTECMAN project. Aging Clinical and Experimental Research, 2021, 33, 2011-2015.	2.9	2
23	Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis. Cardiovascular Drugs and Therapy, 2021, 35, 1067-1076.	2.6	40
24	High-sensitivity methods for cardiac troponins: The mission is not over yet. Advances in Clinical Chemistry, 2021, 103, 215-252.	3.7	19
25	Management of complications of cardiac amyloidosis: 10 questions and answers. European Journal of Preventive Cardiology, 2021, 28, 1000-1005.	1.8	12
26	The value of hospital personnel serological screening in an integrated COVID-19 infection prevention and control strategy. Infection Control and Hospital Epidemiology, 2021, 42, 373-374.	1.8	11
27	Myocardial salvage is increased after sympathetic renal denervation in a pig model of acute infarction. Clinical Research in Cardiology, 2021, 110, 711-724.	3.3	4
28	Central apnoeas and ticagrelor-related dyspnoea in patients with acute coronary syndrome. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 180-188.	3.0	14
29	A simple echocardiographic score to rule out cardiac amyloidosis. European Journal of Clinical Investigation, 2021, 51, e13449.	3.4	24
30	Renin profiling predicts neurohormonal response to sacubitril/valsartan. ESC Heart Failure, 2021, 8, 719-724.	3.1	3
31	Potential Utility of Cardiorenal Biomarkers for Prediction and Prognostication of Worsening Renal Function in Acute Heart Failure. Journal of Cardiac Failure, 2021, 27, 533-541.	1.7	11
32	Effects of central apneas on sympathovagal balance and hemodynamics at night: impact of underlying systolic heart failure. Sleep and Breathing, 2021, 25, 965-977.	1.7	4
33	Effects of nasal high flow on sympathovagal balance, sleep, and sleep-related breathing in patients with precapillary pulmonary hypertension. Sleep and Breathing, 2021, 25, 705-717.	1.7	2
34	Sleep-Disordered Breathing and Nocturnal Hypoxemia in Precapillary Pulmonary Hypertension: Prevalence, Pathophysiological Determinants, and Clinical Consequences. Respiration, 2021, 100, 865-876.	2.6	15
35	The pathophysiological and clinical relevance of combined measurement of natriuretic peptides and cardiac troponins for risk prediction of incident heart failure in communityâ€dwelling individuals. European Journal of Heart Failure, 2021, 23, 403-405.	7.1	2
36	Breath-hold task induces temporal heterogeneity in electroencephalographic regional field power in healthy subjects. Journal of Applied Physiology, 2021, 130, 298-307.	2.5	1

#	Article	IF	Citations
37	Use of biomarkers to diagnose and manage cardiac amyloidosis. European Journal of Heart Failure, 2021, 23, 217-230.	7.1	33
38	Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient. JACC: Case Reports, 2021, 3, 450-454.	0.6	2
39	Re-appraisal of the obesity paradox in heart failure: a meta-analysis of individual data. Clinical Research in Cardiology, 2021, 110, 1280-1291.	3.3	20
40	Norepinephrine, plasma renin activity and cardiovascular mortality in systolic heart failure. Heart, 2021, 107, 989-995.	2.9	2
41	Central apneas, chemoreflex sensitivity, and buspirone in spinal cord injury: a word of caution. Journal of Applied Physiology, 2021, 130, 756-757.	2.5	1
42	Decongestion discriminates risk for oneâ€year mortality in patients with improving renal function in acute heart failure. European Journal of Heart Failure, 2021, 23, 1122-1130.	7.1	14
43	Evaluation and Comparison with Other High-Sensitivity Methods of Analytical Performance and Measured Values of a New Laboratory Test for Cardiac Troponin I Assay. journal of applied laboratory medicine, The, 2021, 6, 1237-1250.	1.3	7
44	Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis. European Journal of Clinical Investigation, 2021, 51, e13598.	3.4	16
45	Prognostic value of reverse remodelling criteria in heart failure with reduced or midâ€range ejection fraction. ESC Heart Failure, 2021, 8, 3014-3025.	3.1	11
46	Sacubitrilâ€“valsartan treatment is associated with decrease in central apneas in patients with heart failure with reduced ejection fraction. International Journal of Cardiology, 2021, 330, 112-119.	1.7	14
47	Relation of Decongestion and Time to Diuretics to Biomarker Changes and Outcomes in Acute Heart Failure. American Journal of Cardiology, 2021, 147, 70-79.	1.6	7
48	Indications of beta-adrenoceptor blockers in Takotsubo syndrome and theoretical reasons to prefer agents with vasodilating activity. International Journal of Cardiology, 2021, 333, 45-50.	1.7	11
49	Molecular Autopsy of Sudden Cardiac Death in the Genomics Era. Diagnostics, 2021, 11, 1378.	2.6	16
50	Evaluation of pathophysiological relationships between renin-angiotensin and ACE-ACE2 systems in cardiovascular disorders: from theory to routine clinical practice in patients with heart failure. Critical Reviews in Clinical Laboratory Sciences, 2021, 58, 530-545.	6.1	9
51	The ergoreflex: how the skeletal muscle modulates ventilation and cardiovascular function in health and disease. European Journal of Heart Failure, 2021, 23, 1458-1467.	7.1	29
52	Discharge FGF23 level predicts one year outcome in patients admitted with acute heart failure. International Journal of Cardiology, 2021, 336, 98-104.	1.7	6
53	Novel Drug Targets for Central Apneas in Heart Failure: On the Road. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 490-491.	5.6	0
54	Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 252-258.	3.0	9

#	Article	IF	Citations
55	NT-proBNP for Risk Prediction in HeartÂFailure. JACC: Heart Failure, 2021, 9, 653-663.	4.1	20
56	Mapping dependencies of BOLD signal change to end-tidal CO2: Linear and nonlinear modeling, and effect of physiological noise correction. Journal of Neuroscience Methods, 2021, 362, 109317.	2.5	1
57	Hide and seek. Ticagrelor and central apneas after acute coronary syndrome. Sleep Medicine, 2021, 86, 125.	1.6	0
58	Benefit of buspirone on chemoreflex and central apnoeas in heart failure: a randomized controlled crossover trial. European Journal of Heart Failure, 2021, 23, 312-320.	7.1	28
59	Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets. Heart Failure Reviews, 2021, 26, 881-890.	3.9	43
60	Evidence on clinical relevance of cardiovascular risk evaluation in the general population using cardio-specific biomarkers. Clinical Chemistry and Laboratory Medicine, 2021, 59, 79-90.	2.3	42
61	High-sensitivity cardiac troponin I and T methods for the early detection of myocardial injury in patients on chemotherapy. Clinical Chemistry and Laboratory Medicine, 2021, 59, 513-521.	2.3	8
62	Clinical relevance of biological variation of cardiac troponins. Clinical Chemistry and Laboratory Medicine, 2021, 59, 641-652.	2.3	36
63	Amyloid Deposits and Fibrosis on Left Ventricular Endomyocardial Biopsy Correlate With Extracellular Volume in Cardiac Amyloidosis. Journal of the American Heart Association, 2021, 10, e020358.	3.7	34
64	Cardiotoxic effects and myocardial injury: the search for a more precise definition of drug cardiotoxicity. Clinical Chemistry and Laboratory Medicine, 2021, 59, 51-57.	2.3	8
65	Cardiac biomarkers retain prognostic significance in patients with heart failure and chronic obstructive pulmonary disease. Journal of Cardiovascular Medicine, 2021, Publish Ahead of Print, 28-36.	1.5	1
66	Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings. European Journal of Preventive Cardiology, 2020, 27, 1806-1815.	1.8	60
67	Procalcitonin, white blood cell count and C-reactive protein as predictors of S. aureus infection and mortality in infective endocarditis. International Journal of Cardiology, 2020, 301, 190-194.	1.7	22
68	Gender and age normalization and ventilation efficiency during exercise in heart failure with reduced ejection fraction. ESC Heart Failure, 2020, 7, 368-377.	3.1	23
69	Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than Nâ€terminal proâ€Bâ€type natriuretic peptide and highâ€sensitivity troponin T. European Journal of Heart Failure, 2020, 22, 2078-2088.	7.1	26
70	Shortâ€term prognostic implications of serum and urine neutrophil gelatinaseâ€associated lipocalin in acute heart failure: findings from the AKINESIS study. European Journal of Heart Failure, 2020, 22, 251-263.	7.1	19
71	Multiparametric Echocardiography Scores for the Diagnosis of CardiacÂAmyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 909-920.	5.3	136
72	Targeting Cyclic Guanosine Monophosphate to Treat HeartÂFailure. Journal of the American College of Cardiology, 2020, 76, 1795-1807.	2.8	71

#	Article	IF	Citations
73	Harmonization of two hs-cTnI methods based on recalibration of measured quality control and clinical samples. Clinica Chimica Acta, 2020, 510, 150-156.	1.1	11
74	Reply. Journal of the American College of Cardiology, 2020, 76, 2040-2041.	2.8	0
75	Piloting a web-based systematic collection and reporting of patient-reported outcome measures and patient-reported experience measures in chronic heart failure. BMJ Open, 2020, 10, e037754.	1.9	11
76	Analysis of the logistical, economic and minimally invasive cardiac surgical training difficulties in India. Archives of Medical Sciences Atherosclerotic Diseases, 2020, 5, 178-185.	1.0	0
77	Body mass index and outcomes in ischaemic versus non-ischaemic heart failure across the spectrum of ejection fraction. European Journal of Preventive Cardiology, 2020, , 204748732092761.	1.8	21
78	Impact of right atrium dimension on adverse outcome after pulmonary valve replacement in repaired Tetralogy of Fallot patients. International Journal of Cardiovascular Imaging, 2020, 36, 1973-1982.	1.5	6
79	Upright Cheyne-Stokes Respiration in Patients With HeartÂFailure. Journal of the American College of Cardiology, 2020, 75, 2934-2946.	2.8	31
80	Pirfenidone is a cardioprotective drug: Mechanisms of action and preclinical evidence. Pharmacological Research, 2020, 155, 104694.	7.1	52
81	Diphosphonate single-photon emission computed tomography in cardiac transthyretin amyloidosis. International Journal of Cardiology, 2020, 307, 187-192.	1.7	9
82	Adaptive servo-ventilation therapy does not favourably alter sympatho-vagal balance in sleeping patients with systolic heart failure and central apnoeas: Preliminary data. International Journal of Cardiology, 2020, 315, 59-66.	1.7	10
83	Ld-EEG Effective Brain Connectivity in Patients With Cheyne-Stokes Respiration. IEEE Transactions on Neural Systems and Rehabilitation Engineering, 2020, 28, 1216-1225.	4.9	6
84	Cardiovascular Death Risk in Recovered Mid-Range Ejection Fraction Heart Failure: Insights From Cardiopulmonary Exercise Test. Journal of Cardiac Failure, 2020, 26, 932-943.	1.7	8
85	Early evaluation of myocardial injury by means of high-sensitivity methods for cardiac troponins after strenuous and prolonged exercise. Journal of Sports Medicine and Physical Fitness, 2020, 60, 1297-1305.	0.7	4
86	The combined measurement of high-sensitivity cardiac troponins and natriuretic peptides: a useful tool for clinicians?. Journal of Cardiovascular Medicine, 2020, 21, 953-963.	1.5	14
87	Contribution of the Lung to the Genesis of Cheyneâ€Stokes Respiration in Heart Failure: Plant Gain Beyond Chemoreflex Gain and Circulation Time. Journal of the American Heart Association, 2019, 8, e012419.	3.7	28
88	Evaluation of analytical performance of immunoassay methods for cTnI and cTnT: From theory to practice. Advances in Clinical Chemistry, 2019, 93, 239-262.	3.7	46
89	Clinical and Prognostic Significance of sST2 in HeartÂFailure. Journal of the American College of Cardiology, 2019, 74, 2193-2203.	2.8	110
90	Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction. International Journal of Cardiology, 2019, 296, 91-97.	1.7	60

#	Article	IF	Citations
91	Central and Obstructive Apneas in Heart Failure With Reduced, Mid-Range and Preserved Ejection Fraction. Frontiers in Cardiovascular Medicine, 2019, 6, 125.	2.4	25
92	Noncardiac Versus Cardiac Mortality in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction. Journal of the American Heart Association, 2019, 8, e013441.	3.7	62
93	Left ventricular ejection fraction and coronary artery disease in the era of precision medicine. European Journal of Preventive Cardiology, 2019, 26, 1271-1272.	1.8	1
94	Utility of Urine Neutrophil Gelatinase-Associated Lipocalin for Worsening Renal Function during Hospitalization for Acute Heart Failure: Primary Findings of the Urine N-gal Acute Kidney Injury N-gal Evaluation of Symptomatic Heart Failure Study (AKINESIS). Journal of Cardiac Failure, 2019, 25, 654-665.	1.7	23
95	Revisiting the obesity paradox in heart failure: Per cent body fat as predictor of biomarkers and outcome. European Journal of Preventive Cardiology, 2019, 26, 1751-1759.	1.8	28
96	Admission high-sensitivity troponin T and NT-proBNP for outcome prediction in acute heart failure. International Journal of Cardiology, 2019, 293, 137-142.	1.7	24
97	No Aldosterone Breakthrough With the Neprilysin Inhibitor Sacubitril. Journal of the American College of Cardiology, 2019, 73, 3037-3038.	2.8	5
98	Treatment of cardiac transthyretin amyloidosis: an update. European Heart Journal, 2019, 40, 3699-3706.	2.2	121
99	Impact of Exercise Rehabilitation on Exercise Capacity and Quality-of-Life in Heart Failure. Journal of the American College of Cardiology, 2019, 73, 1430-1443.	2.8	172
100	Cardiac Magnetic Resonance Evaluation of Pulmonary Transit Time and Blood Volume in Adult Congenital Heart disease. Journal of Magnetic Resonance Imaging, 2019, 50, 779-786.	3.4	14
101	Cheyne-Stokes respiration related oscillations in cardiopulmonary hemodynamics in patients with heart failure. International Journal of Cardiology, 2019, 289, 76-82.	1.7	21
102	Cardiac troponins as biomarkers for cardiac disease. Biomarkers in Medicine, 2019, 13, 325-330.	1.4	28
103	Value in Healthcare and the Role of the Patient Voice. HealthcarePapers, 2019, 18, 28-35.	0.3	13
104	Exercise oscillatory ventilation and prognosis in heart failure patients with reduced and midâ€range ejection fraction. European Journal of Heart Failure, 2019, 21, 1586-1595.	7.1	24
105	Bâ€type natriuretic peptide trend predicts clinical significance of worsening renal function in acute heart failure. European Journal of Heart Failure, 2019, 21, 1553-1560.	7.1	29
106	Pathophysiological mechanisms determining sex differences in circulating levels of cardiac natriuretic peptides and cardiac troponins. Journal of Laboratory and Precision Medicine, 2019, 4, 8-8.	1.1	10
107	Evaluation of analytical performances using standardized analytical protocols and comparison of clinical results of the new ADVIA BNP and NT-proBNP immunoassays for the Centaur XPT platform. Clinical Chemistry and Laboratory Medicine, 2019, 57, 911-917.	2.3	3
108	Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years. European Journal of Heart Failure, 2019, 21, 208-217.	7.1	60

#	Article	IF	Citations
109	High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure. International Journal of Cardiology, 2019, 277, 166-172.	1.7	32
110	Exercise intolerance in heart failure with preserved ejection fraction: A reappraisal of central mechanisms?. International Journal of Cardiology, 2018, 254, 248-249.	1.7	2
111	Mineralocorticoid receptor antagonists for heart failure: a realâ€life observational study. ESC Heart Failure, 2018, 5, 267-274.	3.1	13
112	Evaluation of the analytical performance of a new ADVIA immunoassay using the Centaur XPT platform system for the measurement of cardiac troponin I. Clinical Chemistry and Laboratory Medicine, 2018, 56, e229-e231.	2.3	32
113	SYMPATHETIC RENAL DENERVATION AFTER ACUTE MYOCARDIAL INFARCTION BLUNTS ADRENERGIC ACTIVATION AND INCREASED MYOCARDIAL SALVAGE IN PIGS. Journal of the American College of Cardiology, 2018, 71, A175.	2.8	0
114	Sex-related differences in chronic heart failure. International Journal of Cardiology, 2018, 255, 145-151.	1.7	41
115	Obese phenotype and natriuretic peptides in patients with heart failure with preserved ejection fraction. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1015-1025.	2.3	18
116	Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure. Circulation, 2018, 137, 286-297.	1.6	157
117	Respiratory Training Late After Fontan Intervention: Impact on Cardiorespiratory Performance. Pediatric Cardiology, 2018, 39, 695-704.	1.3	18
118	Evaluation of analytical performance of a chemiluminescence enzyme immunoassay (CLEIA) for cTnI using the automated AIA-CL2400 platform. Clinical Chemistry and Laboratory Medicine, 2018, 56, e174-e176.	2.3	12
119	N-terminal fraction of pro-B-type natriuretic peptide versus clinical risk scores for prognostic stratification in chronic systolic heart failure. European Journal of Preventive Cardiology, 2018, 25, 889-895.	1.8	12
120	Late gadolinium enhancement as a predictor of functional recovery, need for defibrillator implantation and prognosis in non-ischemic dilated cardiomyopathy. International Journal of Cardiology, 2018, 250, 195-200.	1.7	37
121	Evaluation of analytical performance of a new high-sensitivity immunoassay for cardiac troponin I. Clinical Chemistry and Laboratory Medicine, 2018, 56, 492-501.	2.3	36
122	Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a longâ€term comparison. European Journal of Heart Failure, 2018, 20, 700-710.	7.1	84
123	Noncardiovascular death after acute heart failure. Do not lose the war while fighting for the failing heart. International Journal of Cardiology, 2018, 250, 231-232.	1.7	1
124	Heart, kidney and FGF23: Les liaisons dangereuses. International Journal of Cardiology, 2018, 253, 120-121.	1.7	1
125	sST2 Predicts Outcome in ChronicÂHeartÂFailure Beyond NTâ^'proBNP and High-Sensitivity Troponin T. Journal of the American College of Cardiology, 2018, 72, 2309-2320.	2.8	126
126	Impact of exerciseâ€based cardiac rehabilitation in patients with heart failure (ExTraMATCH II) on mortality and hospitalisation: an individual patient data metaâ€analysis of randomised trials. European Journal of Heart Failure, 2018, 20, 1735-1743.	7.1	125

#	Article	IF	Citations
127	NT-proBNP prognostic value is maintained in elderly and very elderly patients with chronic systolic heart failure. International Journal of Cardiology, 2018, 271, 324-330.	1.7	27
128	Heart rate response to exercise and prognosis: Does rhythm matter?. European Journal of Preventive Cardiology, 2018, 25, 1632-1633.	1.8	1
129	Tireless cardiologists needed for (very) tired patients: The case of heart failure. European Journal of Preventive Cardiology, 2018, 25, 1702-1703.	1.8	0
130	The IL-33/ST2 pathway, inflammation and atherosclerosis: Trigger and target?. International Journal of Cardiology, 2018, 267, 188-192.	1.7	40
131	Quality of life and outcome in heart failure with preserved ejection fraction: When sex matters. International Journal of Cardiology, 2018, 267, 141-142.	1.7	6
132	Dose-dependent efficacy of Î²-blocker in patients with chronic heart failure and atrial fibrillation. International Journal of Cardiology, 2018, 273, 141-146.	1.7	13
133	The CARPEDIEM Algorithm: A Rule-Based System for Identifying Heart Failure Phenotype with a Precision Public Health Approach. Frontiers in Public Health, 2018, 6, 6.	2.7	11
134	Healthy hearts at hectic pace: From daily life stress to abnormal cardiomyocyte function and arrhythmias. European Journal of Preventive Cardiology, 2018, 25, 1419-1430.	1.8	11
135	Vitamin D measurement and effect on outcome in a cohort of patients with heart failure. Endocrine Connections, 2018, 7, 957-964.	1.9	15
136	Left ventricular ejection fraction for risk stratification in chronic systolic heart failure. International Journal of Cardiology, 2018, 273, 136-140.	1.7	11
137	The paradox of low Bâ€type natriuretic peptide levels in obesity revisited: does sex matter?. European Journal of Heart Failure, 2018, 20, 1215-1216.	7.1	6
138	Medium-term effect of sublingual l -glutathione supplementation on flow-mediated dilation in subjects with cardiovascular risk factors. Nutrition, 2017, 38, 41-47.	2.4	17
139	Breathing Not Properly in the oldest old. Is brain natriuretic peptide a poor test for the diagnosis of heart failure in the elderly?. European Journal of Heart Failure, 2017, 19, 549-551.	7.1	1
140	Prognostic role of Î²â€blocker selectivity and dosage regimens in heart failure patients. Insights from the <scp>MECKI</scp> score database. European Journal of Heart Failure, 2017, 19, 904-914.	7.1	28
141	Autonomic, functional, skeletal muscle, and cardiac abnormalities are associated with increased ergoreflex sensitivity in mitochondrial disease. European Journal of Heart Failure, 2017, 19, 1701-1709.	7.1	18
142	Meta-Analysis of Soluble Suppression ofÂTumorigenicity-2 and Prognosis in Acute Heart Failure. JACC: Heart Failure, 2017, 5, 287-296.	4.1	104
143	Effective Cardiac Index and Systemic-Pulmonary Collaterals Evaluated by Cardiac Magnetic Resonance Late After Fontan Palliation. American Journal of Cardiology, 2017, 119, 2069-2072.	1.6	13
144	Predicting readmissions after hospitalization for heart failure: Medical reasoning vs calculators. International Journal of Cardiology, 2017, 236, 348-349.	1.7	0

#	Article	IF	Citations
145	The 99th percentile of reference population for cTnI and cTnT assay: methodology, pathophysiology and clinical implications. Clinical Chemistry and Laboratory Medicine, 2017, 55, 1634-1651.	2.3	63
146	Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?. European Journal of Preventive Cardiology, 2017, 24, 1528-1531.	1.8	10
147	Hypovitaminosis D in patients with heart failure: effects on functional capacity and patientsâ€™ survival. Endocrine, 2017, 58, 574-581.	2.3	23
148	Predictive Value of NT-proBNP in Patients with Acute Myocardial Infarction. Clinical Chemistry, 2017, 63, 1045-1046.	3.2	2
149	To Breathe, or Not to Breathe: That Is the Question. , 2017, , 203-217.		0
150	Effect of Sex on Reverse Remodeling in Chronic Systolic Heart Failure. JACC: Heart Failure, 2017, 5, 735-742.	4.1	30
151	Are big data on myocardial infarction enough for small heart failure patients? Lessons from a national registry. International Journal of Cardiology, 2017, 248, 278-279.	1.7	1
152	New issues on measurement of B-type natriuretic peptides. Clinical Chemistry and Laboratory Medicine, 2017, 56, 32-39.	2.3	20
153	Prognostic Significance of Central Apneas Throughout a 24-Hour Period in PatientsÂWith Heart Failure. Journal of the American College of Cardiology, 2017, 70, 1351-1364.	2.8	51
154	Neurohormonal modulation for treatment of cardiac involvement in dystrophinopathies and mitochondrial disease. European Journal of Preventive Cardiology, 2017, 24, 1718-1724.	1.8	6
155	How to take arms against central apneas in heart failure. Expert Review of Cardiovascular Therapy, 2017, 15, 743-755.	1.5	4
156	N-terminal fragment of B-type natriuretic peptide predicts coexisting subclinical heart and vessel disease. Journal of Cardiovascular Medicine, 2017, 18, 750-757.	1.5	2
157	Cardiac light-chain deposition disease relapsing in the transplanted heart. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 135-137.	3.0	4
158	Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure. JACC: Heart Failure, 2017, 5, 280-286.	4.1	127
159	Heart failure and anemia: Effects on prognostic variables. European Journal of Internal Medicine, 2017, 37, 56-63.	2.2	33
160	ANMCO/ELAS/SIBioC Consensus Document: biomarkers in heart failure. European Heart Journal Supplements, 2017, 19, D102-D112.	0.1	13
161	Human Pathophysiological Adaptations to the Space Environment. Frontiers in Physiology, 2017, 8, 547.	2.8	213
162	Breathless Heart: Final Remarks. , 2017, , 285-287.		0

#	Article	IF	Citations
163	Diagnostic Tools: The Easier, the Better. , 2017, , 219-234.		0
164	Targeting and Treating Apneas. , 2017, , 247-270.		0
165	A Cross-Correlational Analysis between Electroencephalographic and End-Tidal Carbon Dioxide Signals: Methodological Issues in the Presence of Missing Data and Real Data Results. Sensors, 2016, 16, 1828.	3.8	10
166	Exercise tolerance can explain the obesity paradox in patients with systolic heart failure: data from the <scp>MECKI</scp> Score Research Group. European Journal of Heart Failure, 2016, 18, 545-553.	7.1	64
167	The search for efficient diagnostic and prognostic biomarkers of heart failure. Future Cardiology, 2016, 12, 327-337.	1.2	1
168	Cheyneâ€“Stokes Respiration, Chemoreflex, and Ticagrelor-Related Dyspnea. New England Journal of Medicine, 2016, 375, 1004-1006.	27.0	36
169	Natriuretic peptides as biomarkers of cardiac endocrine function in heart failure: new challenges and perspectives. Future Cardiology, 2016, 12, 573-584.	1.2	11
170	Neutrophil Gelatinase-Associated Lipocalin for Acute Kidney Injury During Acute Heart Failure Hospitalizations. Journal of the American College of Cardiology, 2016, 68, 1420-1431.	2.8	85
171	Exploratory analysis of nonlinear coupling between EEG global field power and end-tidal carbon dioxide in free breathing and breath-hold tasks. , 2016, 2016, 728-731.		1
172	Influence of central apneas and chemoreflex activation on pulmonary artery pressure in chronic heart failure. International Journal of Cardiology, 2016, 202, 200-206.	1.7	24
173	Inhibition of Galectin-3 Pathway Prevents Isoproterenol-Induced Left Ventricular Dysfunction and Fibrosis in Mice. Hypertension, 2016, 67, 606-612.	2.7	90
174	Sex Profile and Risk Assessment With Cardiopulmonary Exercise Testing in Heart Failure: Propensity Score Matching for Sex Selection Bias. Canadian Journal of Cardiology, 2016, 32, 754-759.	1.7	19
175	The metabolic exercise test data combined with Cardiac And Kidney Indexes (MECKI) score and prognosis in heart failure. A validation study. International Journal of Cardiology, 2016, 203, 1067-1072.	1.7	36
176	N-terminal prob-type natriuretic peptide is a marker of vascular remodelling and subclinical atherosclerosis in asymptomatic hypertensives. European Journal of Preventive Cardiology, 2016, 23, 366-376.	1.8	16
177	Prediction of the Chemoreflex Gain by Common Clinical Variables in Heart Failure. PLoS ONE, 2016, 11, e0153510.	2.5	7
178	Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches. Current Pharmaceutical Design, 2016, 22, 4807-4822.	1.9	16
179	Correlational analysis of electroencephalographic and end-tidal carbon dioxide signals during breath-hold exercise. , 2015, 2015, 6102-5.		4
180	Exercise Performance Is a Prognostic Indicator in Elderly Patients With Chronic Heart Failureã€€â€“ Application of Metabolic Exercise Cardiac Kidney Indexes Score â€“. Circulation Journal, 2015, 79, 2608-2615.	1.6	21

#	Article	IF	Citations
181	Renal Function and Peak Exercise Oxygen Consumption in Chronic Heart Failure With Reduced Left Ventricular Ejection Fraction. Circulation Journal, 2015, 79, 583-591.	1.6	29
182	Refractory hyperaldosteronism in heart failure is associated with plasma renin activity and angiotensinogen polymorphism. Journal of Cardiovascular Medicine, 2015, 16, 416-422.	1.5	12
183	Glycosylated haemoglobin is associated with neurohormonal activation and poor outcome in chronic heart failure patients with mild left ventricular systolic dysfunction. Journal of Cardiovascular Medicine, 2015, 16, 423-430.	1.5	4
184	Prognostic significance of myocardial extracellular volume fraction in nonischaemic dilated cardiomyopathy. Journal of Cardiovascular Medicine, 2015, 16, 681.	1.5	61
185	Cardioprotection by remote ischemic conditioning: Mechanisms and clinical evidences. World Journal of Cardiology, 2015, 7, 621.	1.5	31
186	Prognostic role of atrial fibrillation in patients affected by chronic heart failure. Data from the MECKI score research group. European Journal of Internal Medicine, 2015, 26, 515-520.	2.2	16
187	Evaluation of analytical performance and comparison of clinical results of the new generation method AccuTnI + 3 for the measurement of cardiac troponin I using both patients and quality control plasma samples. Clinica Chimica Acta, 2015, 451, 129-134.	1.1	10
188	State of the art of immunoassay methods for B-type natriuretic peptides: An update. Critical Reviews in Clinical Laboratory Sciences, 2015, 52, 56-69.	6.1	32
189	Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy. International Journal of Cardiology, 2015, 184, 96-100.	1.7	60
190	State of the art of aldosterone immunoassays. A multicenter collaborative study on the behalf of the Cardiovascular Biomarkers Study Group of the Italian Section of European Society of Ligand Assay (ELAS) and SocietÃ Italiana di Biochimica Clinica (SIBIOC). Clinica Chimica Acta, 2015, 444, 106-112.	1.1	22
191	Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging. Journal of Internal Medicine, 2015, 277, 605-614.	6.0	44
192	Usefulness of High-Sensitive Troponin Elevation After Effort Stress to Unveil Vulnerable Myocardium in Patients With Heart Failure. American Journal of Cardiology, 2015, 116, 567-572.	1.6	9
193	Comparison between BNP values measured in capillary blood samples with a POCT method and those measured in plasma venous samples with an automated platform. Clinical Chemistry and Laboratory Medicine, 2015, 53, e125-7.	2.3	10
194	Renal denervation in resistant arterial hypertension: Effects on neurohormonal activation and cardiac natriuretic peptides. International Journal of Cardiology, 2015, 184, 574-575.	1.7	1
195	After the SERVE-HF Trial, Is There Still a Need for Treatment of Central Apnea?. Journal of Cardiac Failure, 2015, 21, 903-905.	1.7	15
196	Deceptive meaning of oxygen uptake measured at the anaerobic threshold in patients with systolic heart failure and atrial fibrillation. European Journal of Preventive Cardiology, 2015, 22, 1046-1055.	1.8	32
197	Markers of fibrosis, inflammation, and remodeling pathways in heart failure. Clinica Chimica Acta, 2015, 443, 29-38.	1.1	70
198	Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: how useful, how feasible?. Clinica Chimica Acta, 2015, 443, 85-93.	1.1	22

#	Article	IF	Citations
199	Cardiac biomarker testing in the clinical laboratory: Where do we stand? General overview of the methodology with special emphasis on natriuretic peptides. Clinica Chimica Acta, 2015, 443, 17-24.	1.1	75
200	The calculation of the cardiac troponin T 99th percentile of the reference population is affected by age, gender, and population selection: A multicenter study in Italy. Clinica Chimica Acta, 2015, 438, 376-381.	1.1	80
201	Peripheral reflex feedbacks in chronic heart failure: Is it time for a direct treatment?. World Journal of Cardiology, 2015, 7, 824.	1.5	5
202	Abstract 14182: Myocardial Fibrosis and Reverse Remodelling in Nonischaemic Dilated Cardiomyopathy. Circulation, 2015, 132, .	1.6	0
203	Leiomyosarcoma of the inferior vena cava in a patient with Budd-Chiari syndrome. Revista Portuguesa De Cardiologia, 2014, 33, 807-809.	0.5	3
204	Treating chemoreflex in heart failure: modulation or demolition?. Journal of Physiology, 2014, 592, 1903-1904.	2.9	5
205	Role of Stress Echocardiography in Operated Fallot: Feasibility and Detection of Right Ventricular Response. Journal of the American Society of Echocardiography, 2014, 27, 1319-1328.	2.8	27
206	Clinical implications of a recent adjustment to the high-sensitivity cardiac troponin T assay: some results. Clinical Chemistry and Laboratory Medicine, 2014, 52, e21-3.	2.3	4
207	Cocaine assumption and transient myocardial edema in asymptomatic cocaine heavy-users. International Journal of Cardiology, 2014, 173, 614-615.	1.7	9
208	Myocardial signal intensity decay after gadolinium injection: a fast and effective method for the diagnosis of cardiac amyloidosis. International Journal of Cardiovascular Imaging, 2014, 30, 1105-1115.	1.5	23
209	Myocardial damage in a mitochondrial myopathy patient with increased ergoreceptor sensitivity and sympatho-vagal imbalance. International Journal of Cardiology, 2014, 176, 1396-1398.	1.7	4
210	b-Gamma-glutamyltransferase activity in human vulnerable carotid plaques. Atherosclerosis, 2014, 237, 307-313.	0.8	24
211	Cardiac biomarkers and risk assessment in patients undergoing major non-cardiac surgery: time to revise the guidelines?. Clinical Chemistry and Laboratory Medicine, 2014, 52, 959-63.	2.3	14
212	Targeting Periodic Breathing in Heart Failure Patients, and Treating Itâ€"Gently. Journal of Cardiac Failure, 2014, 20, 289-291.	1.7	4
213	Surgery Casualties. Journal of the American College of Cardiology, 2014, 63, 181-183.	2.8	2
214	Can We Measure How Hot the Plaque Is? Not Yet, Butâ€¦. Journal of the American College of Cardiology, 2013, 62, 338-339.	2.8	1
215	Influence of preload and afterload on stroke volume response to low-dose dobutamine stress in patients with non-ischemic heart failure: A cardiac MR study. International Journal of Cardiology, 2013, 166, 475-481.	1.7	8
216	Prognostic Value of Indeterminable Anaerobic Threshold in Heart Failure. Circulation: Heart Failure, 2013, 6, 977-987.	3.9	60

#	Article	IF	Citations
217	Prognostic value of alveolar volume in systolic heart failure: a prospective observational study. BMC Pulmonary Medicine, 2013, 13, 69.	2.0	11
218	Plasma leptin and vascular endothelial growth factor (VEGF) in normal subjects at high altitude (5050â€‰m). Archives of Physiology and Biochemistry, 2013, 119, 219-224.	2.1	3
219	Myocardial Fibrosis as a Key Determinant of Left Ventricular Remodeling in Idiopathic Dilated Cardiomyopathy. Circulation: Cardiovascular Imaging, 2013, 6, 790-799.	2.6	132
220	Correlates and reference limits of plasma gamma-glutamyltransferase fractions from the Framingham Heart Study. Clinica Chimica Acta, 2013, 417, 19-25.	1.1	35
221	A simple method for measuring baroreflex sensitivity holds prognostic value in heart failure. International Journal of Cardiology, 2013, 169, e9-e11.	1.7	12
222	Forced expiratory volume in one second: Prognostic value in systolic heart failure. International Journal of Cardiology, 2013, 168, 1573-1574.	1.7	7
223	Metabolic exercise test data combined with cardiac and kidney indexes, the MECKI score: A multiparametric approach to heart failure prognosis. International Journal of Cardiology, 2013, 167, 2710-2718.	1.7	183
224	CMR-Verified Interstitial Myocardial Fibrosis as a Marker of Subclinical Cardiac Involvement in LMNA Mutation Carriers. JACC: Cardiovascular Imaging, 2013, 6, 124-126.	5.3	38
225	Severe heart failure prognosis evaluation for transplant selection in the era of beta-blockers: Role of peak oxygen consumption. International Journal of Cardiology, 2013, 168, 5078-5081.	1.7	25
226	Prognostic value of plasma renin activity in heart failure patients with chronic kidney disease. International Journal of Cardiology, 2013, 167, 711-715.	1.7	27
227	Systematic differences between BNP immunoassays: Comparison of methods using standard protocols and quality control materials. Clinica Chimica Acta, 2013, 424, 287-291.	1.1	28
228	Breathless Heart. Journal of the American College of Cardiology, 2013, 61, 1167-1168.	2.8	2
229	Giant Solitary Fibrous Tumor of the Epicardium Causing Reversible Heart Failure. Annals of Thoracic Surgery, 2013, 96, e49-e51.	1.3	9
230	Evaluation of analytical performance of a novel immunoenzymometric assay for cTnI. Clinica Chimica Acta, 2013, 416, 48-49.	1.1	7
231	Response to Letters Regarding Article, â€œMyocardial Fibrosis as a Key Determinant of Left Ventricular Remodeling in Idiopathic Dilated Cardiomyopathy: A Contrast-Enhanced Cardiovascular Magnetic Studyâ€• Circulation: Cardiovascular Imaging, 2013, 6, e79.	2.6	3
232	Effect of acute administration of vitamin C on muscle sympathetic activity, cardiac sympathovagal balance, and baroreflex sensitivity in hypertensive patients. American Journal of Clinical Nutrition, 2012, 96, 302-308.	4.7	44
233	Individual patient meta-analysis of exercise training effects on systemic brain natriuretic peptide expression in heart failure. European Journal of Preventive Cardiology, 2012, 19, 428-435.	1.8	56
234	The combined use of neutrophil gelatinase-associated lipocalin and brain natriuretic peptide improves risk stratification in pediatric cardiac surgery. Clinical Chemistry and Laboratory Medicine, 2012, 50, 2009-2017.	2.3	27

#	Article	IF	Citations
235	Limitations of Current Echocardiographic Nomograms for Left Ventricular, Valvular, and Arterial Dimensions in Children: A Critical Review. Journal of the American Society of Echocardiography, 2012, 25, 142-152.	2.8	87
236	Accuracy of bâ€<scp>GGT</scp> fraction for the diagnosis of nonâ€alcoholic fatty liver disease. Liver International, 2012, 32, 629-634.	3.9	45
237	Abnormal hyperventilation in patients with hepatic cirrhosis: Role of enhanced chemosensitivity to carbon dioxide. International Journal of Cardiology, 2012, 154, 22-26.	1.7	9
238	Low triiodothyronine and exercise capacity in heart failure. International Journal of Cardiology, 2012, 154, 153-157.	1.7	20
239	Myocardial delayed enhancement in paucisymptomatic nonischemic dilated cardiomyopathy. International Journal of Cardiology, 2012, 157, 43-47.	1.7	51
240	Circulating Forms of the B-Type Natriuretic Peptide Prohormone. Advances in Clinical Chemistry, 2012, 58, 31-44.	3.7	28
241	Natriuretic Peptide Assays Revisited. Journal of the American College of Cardiology, 2011, 57, 1396-1398.	2.8	18
242	The Month After. Journal of the American College of Cardiology, 2011, 58, 1967-1969.	2.8	0
243	Clinical relevance of time course of BNP levels in neonates with congenital heart diseases. Clinica Chimica Acta, 2011, 412, 2300-2304.	1.1	22
244	When the heart is burning: Amino-terminal pro-brain natriuretic peptide as an early marker of cardiac involvement in active autoimmune rheumatic disease. International Journal of Cardiology, 2011, 148, 161-167.	1.7	17
245	PLASMA RENIN ACTIVITY AND ANGIOTENSINOGEN M235T POLYMORPHISM ARE DETERMINANTS OF ALDOSTERONE ESCAPE IN PATIENTS WITH SYSTOLIC HEART FAILURE. Journal of the American College of Cardiology, 2011, 57, E260.	2.8	0
246	Comparison of NT-proCNP and CNP plasma levels in heart failure, diabetes and cirrhosis patients. Regulatory Peptides, 2011, 166, 15-20.	1.9	33
247	Exercise intolerance at high altitude (5050m): Critical power and Wâ€². Respiratory Physiology and Neurobiology, 2011, 177, 333-341.	1.6	21
248	Effect of Acetazolamide on Chemosensitivity, Cheyne-Stokes Respiration, and Response to Effort in Patients With Heart Failure. American Journal of Cardiology, 2011, 107, 1675-1680.	1.6	51
249	Prognostic Value of Plasma Renin Activity in Heart Failure. American Journal of Cardiology, 2011, 108, 246-251.	1.6	61
250	B-type natriuretic peptide secretion following scuba diving. Biomarkers in Medicine, 2011, 5, 205-209.	1.4	7
251	Silent myocardial damage in cocaine addicts. Heart, 2011, 97, 2056-2062.	2.9	55
252	Measurement of the pro-hormone of brain type natriuretic peptide (proBNP): methodological considerations and pathophysiological relevance. Clinical Chemistry and Laboratory Medicine, 2011, 49, 1949-54.	2.3	20

#	Article	IF	Citations
253	Markers of Arrhythmogenic Risk in Hypertensive Subjects. Current Pharmaceutical Design, 2011, 17, 3062-3073.	1.9	8
254	Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 301, H12-H20.	3.2	165
255	Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 301, H12-H20.	3.2	1
256	Cardiovascular risk factors and Î³-glutamyltransferase fractions in healthy individuals. Clinical Chemistry and Laboratory Medicine, 2010, 48, 713-717.	2.3	32
257	Exercise intolerance in chronic heart failure: mechanisms and therapies. Part I. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 637-642.	2.8	107
258	Exercise intolerance in chronic heart failure: mechanisms and therapies. Part II. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 643-648.	2.8	49
259	Atrial fibrillation and amino-terminal pro-brain natriuretic peptide as independent predictors of prognosis in systolic heart failure. International Journal of Cardiology, 2010, 140, 344-350.	1.7	11
260	Different Substrates of Non-Sustained Ventricular Tachycardia in Post-infarction Patients With and Without Left Ventricular Dilatation. Journal of Cardiac Failure, 2010, 16, 61-68.	1.7	12
261	Concordant Versus Discordant Left Bundle Branch Block in Heart Failure Patients: Novel Clinical Value of an Old Electrocardiographic Diagnosis. Journal of Cardiac Failure, 2010, 16, 320-326.	1.7	15
262	Prevalent cardiac phenotype resulting in heart transplantation in a novel LMNA gene duplication. Neuromuscular Disorders, 2010, 20, 512-516.	0.6	12
263	Single-Shot Cardiorenal Scintigraphy with ^{99m}Tc-Tetrofosmin: A Dynamic Characterization at Rest and During Adenosine Infusion. Journal of Nuclear Medicine, 2009, 50, 1288-1295.	5.0	2
264	Old and new biomarkers of heart failure. European Journal of Heart Failure, 2009, 11, 331-335.	7.1	79
265	Prognostic Value of Combined Measurement of Brain Natriuretic Peptide and Triiodothyronine in Heart Failure. Journal of Cardiac Failure, 2009, 15, 35-40.	1.7	53
266	Additive prognostic value of gamma-glutamyltransferase in coronary artery disease. International Journal of Cardiology, 2009, 136, 80-85.	1.7	53
267	Risk factors and prognostic value of daytime Cheyneâ€“Stokes respiration in chronic heart failure patients. International Journal of Cardiology, 2009, 137, 47-53.	1.7	63
268	Combined Increased Chemosensitivity to Hypoxia and Hypercapnia as a Prognosticator in Heart Failure. Journal of the American College of Cardiology, 2009, 53, 1975-1980.	2.8	131
269	New and emerging biomarkers of heart failure. Critical Reviews in Clinical Laboratory Sciences, 2009, 46, 107-128.	6.1	14
270	Predictive value of elevated neutrophilâ€“lymphocyte ratio on cardiac mortality in patients with stable coronary artery disease. Clinica Chimica Acta, 2008, 395, 27-31.	1.1	306

#	Article	IF	Citations
271	Fractions of plasma gamma-glutamyltransferase in healthy individuals: Reference values. Clinica Chimica Acta, 2008, 395, 188-189.	1.1	30
272	Clinical relevance of non-cardiac determinants of natriuretic peptide levels. Clinical Chemistry and Laboratory Medicine, 2008, 46, 1515-23.	2.3	24
273	Natriuretic peptide testing in primary care patients. Clinical Chemistry and Laboratory Medicine, 2008, 46, 1533-42.	2.3	2
274	Permanent atrial fibrillation affects exercise capacity in chronic heart failure patients. European Heart Journal, 2008, 29, 2367-2372.	2.2	73
275	C-type natriuretic peptide expression in patients with chronic heart failure: effects of aerobic training. European Journal of Cardiovascular Prevention and Rehabilitation, 2008, 15, 168-172.	2.8	28
276	Ventricular Repolarization in Hypertension: Beyond Bazett. American Journal of Hypertension, 2008, 21, 9-9.	2.0	0
277	Clinical significance of chemosensitivity in chronic heart failure: influence on neurohormonal derangement, Cheyneâ€“Stokes respiration and arrhythmias. Clinical Science, 2008, 114, 489-497.	4.3	98
278	Comparison of the Diagnostic Accuracy of Brain Natriuretic Peptide (BNP) and the N-Terminal Part of the Propeptide of BNP Immunoassays in Chronic and Acute Heart Failure: A Systematic Review. Clinical Chemistry, 2007, 53, 813-822.	3.2	118
279	Influence of Scal and Natriuretic Peptide (NP) Clearance Receptor Polymorphisms of the NP System on NP Concentration in Chronic Heart Failure. Clinical Chemistry, 2007, 53, 1886-1890.	3.2	22
280	Comparison of Brain Natriuretic Peptide (BNP) and Amino-Terminal ProBNP for Early Diagnosis of Heart Failure. Clinical Chemistry, 2007, 53, 1289-1297.	3.2	71
281	Î³-glutamyltransferase and pathogenesis of cardiovascular diseases. Future Cardiology, 2007, 3, 263-270.	1.2	11
282	The authors of the article cited above respond:. Clinical Chemistry, 2007, 53, 1720-1721.	3.2	3
283	Persistence of baroreceptor control of cerebral blood flow velocity at a simulated altitude of 5000 m. Journal of Hypertension, 2007, 25, 1862-1870.	0.5	3
284	Effects of physical training on cardiovascular control after heart transplantation. International Journal of Cardiology, 2007, 118, 356-362.	1.7	62
285	Amino-Terminal Fragment of Pro-Brain Natriuretic Hormone Identifies Functional Impairment and Right Ventricular Overload in Operated Tetralogy of Fallot Patients. Pediatric Cardiology, 2007, 28, 339-345.	1.3	26
286	Reduced hypoxic ventilatory response with preserved blood oxygenation in yoga trainees and Himalayan Buddhist monks at altitude: evidence of a different adaptive strategy?. European Journal of Applied Physiology, 2007, 99, 511-518.	2.5	30
287	Î²-Lipoprotein- and LDL-associated serum Î³-glutamyltransferase in patients with coronary atherosclerosis. Atherosclerosis, 2006, 186, 80-85.	0.8	85
288	Clinical Applications in Extra-Cardiac Diseases. , 2006, , 133-160.		1

#	Article	IF	Citations
289	Aerobic Training Decreases B-Type Natriuretic Peptide Expression and Adrenergic Activation in Patients With Heart Failure. Journal of the American College of Cardiology, 2006, 47, 1835-1839.	2.8	166
290	C-type natriuretic peptide and heart failure. Pharmacological Research, 2006, 54, 326-333.	7.1	29
291	Frequency-dependent baroreflex control of blood pressure and heart rate during physical exercise. International Journal of Cardiology, 2006, 107, 171-179.	1.7	17
292	Cardiac production of C-type natriuretic peptide in heart failure. Journal of Cardiovascular Medicine, 2006, 7, 397-399.	1.5	40
293	The Potential Roles of Gamma-Glutamyltransferase Activity in the Progression of Atherosclerosis and Cardiovascular Diseases. Vascular Disease Prevention, 2006, 3, 205-209.	0.2	5
294	Gamma-glutamyltransferase as a cardiovascular risk factor. European Heart Journal, 2006, 27, 2145-2146.	2.2	37
295	Cardiac natriuretic hormones as clinical markers: instructions for use. Future Cardiology, 2006, 2, 619-622.	1.2	0
296	Neuro-hormonal activation predicts ventilatory response to exercise and functional capacity in patients with heart failure. European Journal of Heart Failure, 2006, 8, 46-53.	7.1	41
297	Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 290, H17-H29.	3.2	231
298	Clinical relevance of biological variation: the lesson of brain natriuretic peptide (BNP) and NT-proBNP assay. Clinical Chemistry and Laboratory Medicine, 2006, 44, 366-78.	2.3	57
299	C-type natriuretic peptide plasma levels increase in patients with chronic heart failure as a function of clinical severity. European Journal of Heart Failure, 2005, 7, 1145-1148.	7.1	86
300	Analytical Performance and Diagnostic Accuracy of Immunometric Assays for the Measurement of Plasma B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP. Clinical Chemistry, 2005, 51, 445-447.	3.2	70
301	Comparison of a Fully Automated Immunoassay with a Point-of-Care Testing Method for B-Type Natriuretic Peptide. Clinical Chemistry, 2005, 51, 1274-1276.	3.2	37
302	Radioimmunoassay for plasma C-type natriuretic peptide determination: a methodological evaluation. Clinical Chemistry and Laboratory Medicine, 2005, 43, 641-5.	2.3	26
303	Right heart overload contributes to cardiac natriuretic hormone elevation in patients with heart failure. International Journal of Cardiology, 2005, 104, 39-45.	1.7	25
304	The significance of serum Î³-glutamyltransferase in cardiovascular diseases. Clinical Chemistry and Laboratory Medicine, 2004, 42, 1085-91.	2.3	80
305	Cardiac natriuretic hormones, neuro-hormones, thyroid hormones and cytokines in normal subjects and patients with heart failure. Clinical Chemistry and Laboratory Medicine, 2004, 42, 627-36.	2.3	93
306	Analytical performance and clinical results of a fully automated MEIA system for brain natriuretic peptide assay: comparison with a point of care testing method. Clinical Chemistry and Laboratory Medicine, 2004, 42, 1178-85.	2.3	24

#	Article	IF	Citations
307	Human Atherosclerotic Plaques Contain Gamma-Glutamyl Transpeptidase Enzyme Activity. Circulation, 2004, 109, 1440-1440.	1.6	172
308	Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay for the N-terminal fragment of the pro-peptide of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide. Clinical Chemistry and Laboratory Medicine, 2004, 42, 37-44.	2.3	67
309	Cerebral vasoreactivity in Andeans and headache at sea level. Journal of the Neurological Sciences, 2004, 219, 101-106.	0.6	18
310	Angiotensin II radioimmunoassay in patients with heart failure: methodological and clinical assessment. Immuno-Analyse Et Biologie Specialisee, 2004, 19, 105-109.	0.0	0
311	Abnormal ventricular repolarization in hypertensive patients: role of sympatho-vagal imbalance and left ventricular hypertrophy. International Journal of Cardiology, 2004, 97, 57-62.	1.7	26
312	Serum gammaâ€glutamyl transpeptidase: A prognostic marker in cardiovascular diseases. BioFactors, 2003, 17, 199-205.	5.4	11
313	The clinical diagnosis of heart failure is predicted by neurohormonal and immune derangement. Immuno-Analyse Et Biologie Specialisee, 2003, 18, 207-211.	0.0	0
314	Influence of Gender on Circulating Cardiac Natriuretic Hormones in Patients with Heart Failure. Clinical Chemistry and Laboratory Medicine, 2003, 41, 686-92.	2.3	26
315	Natriuretic Peptides (NPs): Automated Electrochemiluminescent Immunoassay for N-Terminal pro-BNP Compared with IRMAs for ANP and BNP in Heart Failure Patients and Healthy Individuals. Clinical Chemistry, 2003, 49, 1552-1554.	3.2	36
316	Ventilation, Autonomic Function, Sleep and Erythropoietin. Advances in Experimental Medicine and Biology, 2003, , 161-175.	1.6	32
317	Respiratory and Cerebrovascular Responses to Hypoxia and Hypercapnia in Familial Dysautonomia. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 141-149.	5.6	65
318	Ventricular repolarization is prolonged in nondipper hypertensive patients. Journal of Hypertension, 2003, 21, 445-451.	0.5	48
319	Ventilation, autonomic function, sleep and erythropoietin. Chronic mountain sickness of Andean natives. Advances in Experimental Medicine and Biology, 2003, 543, 161-75.	1.6	10
320	Serum Gamma-Glutamyltransferase as a Risk Factor of Ischemic Stroke Might Be Independent of Alcohol Consumption. Stroke, 2002, 33, 1163-1164.	2.0	54
321	Respiratory and cardiovascular adaptations to progressive hypoxia. European Heart Journal, 2001, 22, 879-886.	2.2	68
322	Peripheral arterial vascular function at altitude: sea-level natives versus Himalayan high-altitude natives. Journal of Hypertension, 2001, 19, 213-222.	0.5	24
323	Breathing patterns and cardiovascular autonomic modulation during hypoxia induced by simulated altitude. Journal of Hypertension, 2001, 19, 947-958.	0.5	62
324	Prognostic value of serum gamma-glutamyl transferase activity after myocardial infarction. European Heart Journal, 2001, 22, 1802-1807.	2.2	139

#	Article	IF	Citations
325	Hyperthyroidism is associated with lengthening of ventricular repolarization. Clinical Endocrinology, 2001, 55, 27-32.	2.4	40
326	Haematological modifications after acute exposure to high altitude: possible implications for detection of recombinant erythropoietin misuse. British Journal of Haematology, 2000, 109, 895-896.	2.5	7
327	Effects of breathing control on cardiocirculatory modulation in Caucasian lowlanders and Himalayan Sherpas. European Journal of Applied Physiology, 2000, 83, 481-486.	2.5	6
328	Effects of controlled breathing, mental activity and mental stress with or without verbalization on heart rate variability. Journal of the American College of Cardiology, 2000, 35, 1462-1469.	2.8	406
329	Influence of Type of Surgery on the Occurrence of Parasympathetic Reinnervation After Cardiac Transplantation. Circulation, 1998, 97, 1368-1374.	1.6	75
330	Hypoxic Ventilatory Responses and Gas Exchange in Patients with Parkinsonâ€™s Disease. Respiration, 1998, 65, 28-33.	2.6	60
331	Cardiovascular autonomic modulation and activity of carotid baroreceptors at altitude. Clinical Science, 1998, 95, 565-573.	4.3	97
332	Acute and persistent effects of a 46-kilometre wilderness trail run at altitude: cardiovascular autonomic modulation and baroreflexes. Cardiovascular Research, 1997, 34, 273-280.	3.8	63
333	Synchronous and baroceptor-sensitive oscillations in skin microcirculation: evidence for central autonomic control. American Journal of Physiology - Heart and Circulatory Physiology, 1997, 273, H1867-H1878.	3.2	75
334	Origin of Respiratory Sinus Arrhythmia in Conscious Humans. Circulation, 1997, 95, 1813-1821.	1.6	103
335	Autonomic Regulation of Heart Rate and Peripheral Circulation: Comparison of High Altitude and Sea Level Residents. Clinical Science, 1996, 91, 81-83.	0.0	21
336	Demonstrable Cardiac Reinnervation After Human Heart Transplantation by Carotid Baroreflex Modulation of RR Interval. Circulation, 1995, 92, 2895-2903.	1.6	126
337	Flow-Diameter Phase Shift. Hypertension, 1995, 26, 20-25.	2.7	6
338	Low-Frequency Spontaneous Fluctuations of R-R Interval and Blood Pressure in Conscious Humans: A Baroreceptor or Central Phenomenon?. Clinical Science, 1994, 87, 649-654.	4.3	157